San Jose, CA, United States
San Jose, CA, United States
SEARCH FILTERS
Time filter
Source Type

Nearly 90 Percent of Patients 71 and Older Met Clinical Guidelines for Remote Monitoring DUBLIN and CHICAGO- May 17, 2017 - A new Medtronic plc (NYSE: MDT) study shows a high use of app-based remote cardiac monitoring among older patients. Presented at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions, the first-of-its-kind study evaluated 15,595 patients across 1,969 clinics with Medtronic pacemakers who were assigned a MyCareLink Smart(TM) app-based remote monitor. The study found that 88.4 percent of patients of all ages who were prescribed this new technology used their smart devices to successfully activate their MyCareLink Smart mobile app, and 89.7 percent remained "adherent" by transmitting data to the Medtronic CareLink(TM) Network within 12 months, the minimum frequency recommended by the HRS and European Heart Rhythm Association expert consensus. Age was not a clinically significant factor in activating or adhering the app-based monitoring at 12 months, with 89.4 percent of patients aged 71 and older using the app to transmit data, compared to 86.7 percent of patients 18-50 and 91 percent for those 51-70. "There is often a misperception that older patients aren't adapting to newer technologies, but this study shows that is not the case," Khaldoun Tarakji, M.D., M.P.H., electrophysiologist and director of clinical electrophysiology research at the Cleveland Clinic, who led the study. "Hundreds of thousands of pacemakers are implanted every year in the United States, and the majority of them in patients over 65 years of age. Physicians should discuss the importance of remote monitoring with patients, regardless of their age." Dr. Tarakji has received compensation from Medtronic as an invited speaker and educator and is a scientific advisory board member. Approved by the U.S. Food and Drug Administration (FDA) in November 2015, the MyCareLink Smart patient monitor is the world's first app-based remote monitoring system for patients with implantable cardiac devices. With the MyCareLink Smart monitor, patients can use their own smartphone or tablet technology, with cellular or Wi-Fi service, to securely transmit data from their cardiac device to their physicians, who can then interpret the data to make treatment decisions. By connecting patients and physicians, remote cardiac monitoring provides many clinical and economic benefits. These include faster time to treatment if the physician detects a problem with the pacemaker based on the transmitted data;1 less time spent at a doctor's office or clinic for regular checks of the pacemaker;2,3 reduced time spent in the hospital if the physician quickly detects and treats a medical problem;1,4 and a potential increase in patient survival rates.4,5,6 "The MyCareLink Smart Monitor was designed to provide seamless compatibility with devices that patients use every day," said Aisha Barry, vice president and general manager for the Connectivity & Insights business, which is part of the Cardiac and Vascular Group at Medtronic. "We are encouraged this study shows such a high rate of patient use of remote monitoring with our app-based offering, particularly among our older pacemaker patients." In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world. Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


Nearly 90 Percent of Patients 71 and Older Met Clinical Guidelines for Remote Monitoring DUBLIN and CHICAGO- May 17, 2017 - A new Medtronic plc (NYSE: MDT) study shows a high use of app-based remote cardiac monitoring among older patients. Presented at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions, the first-of-its-kind study evaluated 15,595 patients across 1,969 clinics with Medtronic pacemakers who were assigned a MyCareLink Smart(TM) app-based remote monitor. The study found that 88.4 percent of patients of all ages who were prescribed this new technology used their smart devices to successfully activate their MyCareLink Smart mobile app, and 89.7 percent remained "adherent" by transmitting data to the Medtronic CareLink(TM) Network within 12 months, the minimum frequency recommended by the HRS and European Heart Rhythm Association expert consensus. Age was not a clinically significant factor in activating or adhering the app-based monitoring at 12 months, with 89.4 percent of patients aged 71 and older using the app to transmit data, compared to 86.7 percent of patients 18-50 and 91 percent for those 51-70. "There is often a misperception that older patients aren't adapting to newer technologies, but this study shows that is not the case," Khaldoun Tarakji, M.D., M.P.H., electrophysiologist and director of clinical electrophysiology research at the Cleveland Clinic, who led the study. "Hundreds of thousands of pacemakers are implanted every year in the United States, and the majority of them in patients over 65 years of age. Physicians should discuss the importance of remote monitoring with patients, regardless of their age." Dr. Tarakji has received compensation from Medtronic as an invited speaker and educator and is a scientific advisory board member. Approved by the U.S. Food and Drug Administration (FDA) in November 2015, the MyCareLink Smart patient monitor is the world's first app-based remote monitoring system for patients with implantable cardiac devices. With the MyCareLink Smart monitor, patients can use their own smartphone or tablet technology, with cellular or Wi-Fi service, to securely transmit data from their cardiac device to their physicians, who can then interpret the data to make treatment decisions. By connecting patients and physicians, remote cardiac monitoring provides many clinical and economic benefits. These include faster time to treatment if the physician detects a problem with the pacemaker based on the transmitted data;1 less time spent at a doctor's office or clinic for regular checks of the pacemaker;2,3 reduced time spent in the hospital if the physician quickly detects and treats a medical problem;1,4 and a potential increase in patient survival rates.4,5,6 "The MyCareLink Smart Monitor was designed to provide seamless compatibility with devices that patients use every day," said Aisha Barry, vice president and general manager for the Connectivity & Insights business, which is part of the Cardiac and Vascular Group at Medtronic. "We are encouraged this study shows such a high rate of patient use of remote monitoring with our app-based offering, particularly among our older pacemaker patients." In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world. Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


Nearly 90 Percent of Patients 71 and Older Met Clinical Guidelines for Remote Monitoring DUBLIN and CHICAGO- May 17, 2017 - A new Medtronic plc (NYSE: MDT) study shows a high use of app-based remote cardiac monitoring among older patients. Presented at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions, the first-of-its-kind study evaluated 15,595 patients across 1,969 clinics with Medtronic pacemakers who were assigned a MyCareLink Smart(TM) app-based remote monitor. The study found that 88.4 percent of patients of all ages who were prescribed this new technology used their smart devices to successfully activate their MyCareLink Smart mobile app, and 89.7 percent remained "adherent" by transmitting data to the Medtronic CareLink(TM) Network within 12 months, the minimum frequency recommended by the HRS and European Heart Rhythm Association expert consensus. Age was not a clinically significant factor in activating or adhering the app-based monitoring at 12 months, with 89.4 percent of patients aged 71 and older using the app to transmit data, compared to 86.7 percent of patients 18-50 and 91 percent for those 51-70. "There is often a misperception that older patients aren't adapting to newer technologies, but this study shows that is not the case," Khaldoun Tarakji, M.D., M.P.H., electrophysiologist and director of clinical electrophysiology research at the Cleveland Clinic, who led the study. "Hundreds of thousands of pacemakers are implanted every year in the United States, and the majority of them in patients over 65 years of age. Physicians should discuss the importance of remote monitoring with patients, regardless of their age." Dr. Tarakji has received compensation from Medtronic as an invited speaker and educator and is a scientific advisory board member. Approved by the U.S. Food and Drug Administration (FDA) in November 2015, the MyCareLink Smart patient monitor is the world's first app-based remote monitoring system for patients with implantable cardiac devices. With the MyCareLink Smart monitor, patients can use their own smartphone or tablet technology, with cellular or Wi-Fi service, to securely transmit data from their cardiac device to their physicians, who can then interpret the data to make treatment decisions. By connecting patients and physicians, remote cardiac monitoring provides many clinical and economic benefits. These include faster time to treatment if the physician detects a problem with the pacemaker based on the transmitted data;1 less time spent at a doctor's office or clinic for regular checks of the pacemaker;2,3 reduced time spent in the hospital if the physician quickly detects and treats a medical problem;1,4 and a potential increase in patient survival rates.4,5,6 "The MyCareLink Smart Monitor was designed to provide seamless compatibility with devices that patients use every day," said Aisha Barry, vice president and general manager for the Connectivity & Insights business, which is part of the Cardiac and Vascular Group at Medtronic. "We are encouraged this study shows such a high rate of patient use of remote monitoring with our app-based offering, particularly among our older pacemaker patients." In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world. Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


Frejlichowski D.,West Pomeranian University of Technology | Gosciewska K.,West Pomeranian University of Technology | Gosciewska K.,Smart Monitor | Forczmanski P.,West Pomeranian University of Technology | Hofman R.,Smart Monitor
Pattern Analysis and Applications | Year: 2015

SmartMonitor is an innovative surveillance system based on video content analysis. It is a modular solution that can work in several predefined scenarios mainly concerned with home/surrounding protection against unauthorized intrusion, supervision over ill person and crime detection. Each scenario is associated with several actions and conditions, which imply the utilization of algorithms with various input parameters. In this paper, focus is put on the analysis of foreground object patterns for the purposes of event recognition, as well as the experimental investigation of selected methods and algorithms which were developed and employed for the SmartMonitor system prototype. The prototype performs three main tasks: detection and localization of foreground regions using adaptive background modelling based on Gaussian Mixture Models, candidate objects extraction and classification using Haar and HOG descriptors, and tracking using Mean-Shift algorithm. The main goal of the work described here is to match system parameters with each scenario to provide the highest effectiveness and to decrease the number of false alarms. © 2014, The Author(s).


Trademark
Smart Monitor | Date: 2012-04-16

Non-medical movement sensing and measuring device and instrumentation system for detecting human seizures, namely, an electronic device worn on the wrist consisting of hardware, firmware, electronic sensors, global position systems, and microprocessors, which function as a unit to sense and identify certain body movements, store information related thereto and send alerts and information related thereto to another device or devices through electronic or wireless means for review or action, other than for medical purposes. Movement sensing and measuring device and instrumentation system for detecting human seizures, namely, an electronic device worn on the wrist consisting of hardware, firmware, electronic sensors, global position systems, and microprocessors, clock, and operating software which function as a unit to sense and identify certain body movements, stores information related thereto and sends alerts and information related thereto to another device or devices through electronic or wireless means, used for medical purposes.


Trademark
Smart Monitor | Date: 2013-02-15

Movement sensing and measuring device and instrumentation system for detecting human activity, sleep and wake cycles, seizures, tremors, falls, uneven gait, convulsions and abnormal or dysfunctional body movements namely, an electronic device worn on the body consisting of hardware, firmware, electronic sensors, global position systems, and microprocessors, clock, and operating software which function as a unit to sense and identify certain body movements, store information related thereto and provide and send health and medical related notifications, reminders, alerts and information to another device or devices through electronic or wireless means, used for medical and health purposes.


Trademark
Smart Monitor | Date: 2014-07-11

For: Movement sensing and measuring device and instrumentation system for detecting human seizures, namely, an electronic device worn on the wrist consisting of hardware, firmware,electronic sensors, global positioning systems, and microprocessors, clock and operating software which function as a unit to sense and identify certain body movements, stores information related thereto and sends alerts and information related thereto to another device or devices through electronic or wireless means, used for medical purposes, in class 10 (U.S. CLS. 26,39 and 44).


Trademark
Smart Monitor | Date: 2012-11-27

Movement sensing and measuring device and instrumentation system for detecting human seizures, namely, an electronic device worn on the body consisting of firmware, electronic sensors, motion detectors, global position systems, and microprocessors, clock, and operating software which function as a unit to sense and identify certain body movements, stores information related thereto and sends alerts and information related thereto to another device or devices through electronic or wireless means for review and action. Medical apparatus and movement sensing and measuring device and instrumentation system for detecting human seizures, namely, an electronic device worn on the body consisting of firmware, electronic sensors, motion detectors, global position systems, and microprocessors, clock, and operating software which function as a unit to sense and identify certain body movements, stores information related thereto and sends alerts and information related thereto to another device or devices through electronic or wireless means used for medical purposes.


Patent
Smart Monitor | Date: 2015-01-16

In an embodiment, a seizure monitor provides intelligent epilepsy seizure detection, monitoring, and alerting for epilepsy patients or people with seizures. In an embodiment, the seizure monitor may be a wearable, non-intrusive, passive monitoring device that does not require any insertion or ingestion into the human body. In an embodiment, the seizure monitor may include several output options for outputting the accelerometer/gyro or other motion sensor data and video data, so that the data may be immediately validated and/or remotely viewed. The device alerts are communicated to the outside care givers via wireless or wired medium. The device may also support recording of accelerometer or other motion sensor data and video data, which can be reviewed later for further analysis and/or diagnosis. The device and invention is also used and applicable for other body motion disorders or detection and diagnostics.


Loading Smart Monitor collaborators
Loading Smart Monitor collaborators